ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2026
Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes.
Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
background and hypothesisIn patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), there remains a paucity of data from large, high-quality, real-world studies on the efficacy of weight-lowering interventions, including the glucagon-like peptide-1-based therapies semaglutide and tirzepatide, as well as bariatric surgery (BS). This retrospective cohort study evaluates these interventions on cardiorenal outcomes and mortality using health records from TriNetX US Collaborative Network.
methodsThree cohorts with T2DM and CKD living with overweight or obesity, prescribed semaglutide or tirzepatide, or with a BS procedure were propensity-score matched with a cohort receiving dipeptidyl peptidase 4 inhibitors (DPP4i, weight-neutral control). We investigated the hazard ratio (HR) of: (i) end-stage renal disease (ESRD); (ii) myocardial infarction (MI); (iii) stroke; and (iv) all-cause mortality.
resultsCohorts included 17 749 (semaglutide, age 64.1 ± 10.9 years, 57.4% female), 4211 (tirzepatide, 63.7 ± 10.8, 58.1%) and 2603 (BS, 56.1 ± 11.2, 74.1%) patients. Compared with DPP4i, semaglutide reduced the risk of ESRD [HR 0.78 (95% confidence interval 0.71 to 0.85)], while tirzepatide showed a reduction of 42% (0.0.58, 0.45 to 0.75). BS lowered ESRD risk (0.79, 0.67 to 0.92). Semaglutide reduced MI (0.80, 0.72 to 0.88) and stroke (0.85, 0.77 to 0.95) risk, while tirzepatide lowered MI and stroke by 24%. BS was associated with reduced MI (0.45, 0.35 to 0.58) and stroke (0.57, 0.44 to 0.74) risk. All-cause mortality risk was reduced by semaglutide (0.64, 0.59 to 0.70), tirzepatide (0.47, 0.35 to 0.63) and BS (0.68, 0.57 to 0.81).
conclusionsUsing a real-world dataset, semaglutide, tirzepatide and BS-interventions shown to elicit weight loss and improve glycaemic control-have a myriad of benefits on cardio-renal outcomes and mortality, supporting their use as disease-modifying therapy options in T2DM and CKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.